Drug Profile
SRD 441
Alternative Names: SRD-441Latest Information Update: 22 Jul 2015
Price :
$50
*
At a glance
- Originator Surface Therapeutics
- Developer Serentis
- Class Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 22 Jul 2015 Discontinued - Phase-II for Atopic dermatitis in Bulgaria, Finland and Germany prior to July 2015 (Topical)
- 09 Apr 2009 Serentis initiates enrolment in a phase II trial for Atopic dermatitis in Bulgaria, Finland and Germany (NCT00882245)